The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant in recent months.

While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

Amgen has reported that its once-monthly dosing ... dosing of its main rivals Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The Phase II trial (NCT05669599) investigated the candidate ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Despite that assessment, shares in Amgen lost nearly 5% of their value ... better weight loss than Wegovy and roughly in line with Zepbound, which William Blair has now acknowledged is below ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this crowded field comes a new player from the Bay Area that has emerged from stealth ...